Related references
Note: Only part of the references are listed.Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC
Sophie M. Ernst et al.
JOURNAL OF THORACIC ONCOLOGY (2023)
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi et al.
NATURE GENETICS (2023)
Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
H. C. Donker et al.
SCIENTIFIC REPORTS (2023)
Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Lynette M. Sholl
MODERN PATHOLOGY (2022)
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab
Bo Wei et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2022)
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors
Kristof Cuppens et al.
LUNG CANCER (2022)
Therapeutic and prognostic insights from the analysis of cancer mutational signatures
Samuel W. Brady et al.
TRENDS IN GENETICS (2022)
Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
Wei Chong et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2021)
Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
Guus R. M. van den Heuvel et al.
RESPIRATORY RESEARCH (2021)
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
Benshang Li et al.
BLOOD (2020)
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
Binbin Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
Albrecht Stenzinger et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
Valerie Pestinger et al.
MOLECULAR DIAGNOSIS & THERAPY (2020)
Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
Leonie I. Kroeze et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
Carina Heydt et al.
SCIENTIFIC REPORTS (2020)
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou et al.
NATURE CANCER (2020)
A Compendium of Mutational Signatures of Environmental Agents
Jill E. Kucab et al.
CELL (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Assessment of tumor mutation burden calculation from gene panel sequencing data
Zhenwu Xu et al.
ONCOTARGETS AND THERAPY (2019)
Optimizing panel-based tumor mutational burden (TMB) measurement
J. Budczies et al.
ANNALS OF ONCOLOGY (2019)
Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley et al.
NATURE (2019)
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
Volker Endris et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
Arnoud Boot et al.
GENOME RESEARCH (2018)
Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers
Bettina Meier et al.
GENOME RESEARCH (2018)
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
Shixiang Wang et al.
ONCOGENE (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Mutational spectra of aflatoxin B1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma
Supawadee Chawanthayatham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
BEDOPS: high-performance genomic feature operations
Shane Neph et al.
BIOINFORMATICS (2012)
The GENCODE exome: sequencing the complete human exome
Alison J. Coffey et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
BEDTools: a flexible suite of utilities for comparing genomic features
Aaron R. Quinlan et al.
BIOINFORMATICS (2010)